Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01349725 · ClinicalTrials.gov registry record · Phase 1
A Safety Study of ARRY-502 in Healthy Subjects
A Phase 1 study, sponsored by Array Biopharma, now a wholly owned subsidiary of Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT01349725 is a Phase 1 study that has completed, run by Array Biopharma, now a wholly owned subsidiary of Pfizer. The registered enrollment target is 32 participants.
The verdict
NCT01349725, a Phase 1 study, has completed, sponsored by Array Biopharma, now a wholly owned subsidiary of Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
This is a Phase 1 study, involving a 14-day dosing period, designed to test the safety of investigational study drug ARRY-502 in healthy subjects. Approximately 32 healthy subjects from the United States will be enrolled in this study.
Interventions
- DRUG Placebo
- DRUG ARRY-502
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2011-05 |
| Est. Completion | 2011-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01349725
The ClinicalTrials.gov registry entry for NCT01349725 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Array Biopharma, now a wholly owned subsidiary of Pfizer, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01349725 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01349725 about?
NCT01349725 is a clinical study titled "A Safety Study of ARRY-502 in Healthy Subjects". This is a Phase 1 study, involving a 14-day dosing period, designed to test the safety of investigational study drug ARRY-502 in healthy subjects. Approximately 32 healthy subjects from the United States will be enrolled in this study.
What is the current status of trial NCT01349725?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2011-05. Estimated completion is 2011-09.
What interventions are being tested in trial NCT01349725?
The interventions under investigation include: Placebo (DRUG), ARRY-502 (DRUG).
Who is sponsoring clinical trial NCT01349725?
This trial is sponsored by Array Biopharma, now a wholly owned subsidiary of Pfizer, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.